Oxford Immunotec Global, which sells diagnostic tests for latent Tuberculosis infection, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering. The Abingdon, United Kingdom-based company, which was founded in 2002 and booked $29 million in sales for the 12 months ended June 30, 2013, plans to list on the NASDAQ under the symbol OXFD. Oxford Immunotec Global initially filed confidentially on September 10, 2013. J.P. Morgan and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
